Results 151 to 160 of about 835,318 (379)

Age‐Dependent Effects of Loss of Contactin‐Associated Protein‐Like 2, an Autism‐Associated Gene, on the Acquisition and Recall of Fear Memory

Autism Research, EarlyView.
ABSTRACT The contactin‐associated protein‐like 2 (Cntnap2) gene is relevant to autism spectrum disorder (ASD), which is associated with age‐specific structural alterations in limbic brain regions. The Cntnap2 gene encodes for the contactin‐associated protein‐like 2 (CASPR2) protein, and CASPR2 protein levels are high in the amygdala, a limbic region ...
R. J. Taugher‐Hebl, A. Berns, M. Jones, A. Townsend, A. K. Eagen, Sarah L. Ferri, D. R. Langbehn, H. Janouschek   +7 more
wiley   +1 more source

Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study [PDF]

, 1985
T. F. Freund, J. Paul Bolam, Anders Björklund, Ulf Stenevi, Stephen B. Dunnett, John Powell, A. David Smith   +6 more
openalex   +1 more source

Immature mDA neurons ameliorate motor deficits in a 6-OHDA Parkinson's disease mouse model and are functional after cryopreservation

Stem Cell Research, 2019
Parkinson's disease is associated with the loss of dopaminergic neurons in the midbrain. Clinical studies investigating replacement of these neurons with in vitro-generated neurons are currently underway.
Dominique Leitner, Mahesh Ramamoorthy, Marion Dejosez, Thomas P. Zwaka   +3 more
doaj  

First visualization of dopaminergic neurons with a monoclonal antibody to dopamine: a light and electron microscopic study. [PDF]

, 1987
Chantal Decavel, Laurent Lescaudron, N. Mons, A. Calas   +3 more
openalex   +1 more source

Dopamine-dependent neurodegeneration in Drosophila models of familial and sporadic Parkinson's disease

Neurobiology of Disease, 2010
Parkinson's disease has been found to be caused by both, genetic and environmental factors. Despite the diversity of causes involved, a convergent pathogenic mechanism might underlie the special vulnerability of dopaminergic neurons in different forms of
Florian Bayersdorfer, Aaron Voigt, Stephan Schneuwly, José A. Botella   +3 more
doaj  

Cryopreservation practices in clinical and preclinical iPSC‐based cell therapies: Current challenges and future directions

Biotechnology Progress, EarlyView.
Abstract Induced pluripotent stem cells (iPSCs) offer significant therapeutic potential, but cryopreservation challenges, particularly the reliance on cytotoxic Dimethyl Sulfoxide (Me2SO), hinder their clinical application. This review examines current cryopreservation practices in clinical and preclinical iPSC‐based therapies, highlighting the ...
Michael Dobruskin, Geoffrey Toner, Ronald Kander   +2 more
wiley   +1 more source

Cell-type-specific transcriptomes and the Allen Atlas (II): discussion of the linear model of brain-wide densities of cell types [PDF]

arXiv, 2014
The voxelized Allen Atlas of the adult mouse brain (at a resolution of 200 microns) has been used in [arXiv:1303.0013] to estimate the region-specificity of 64 cell types whose transcriptional profile in the mouse brain has been measured in microarray experiments.
arxiv  

Serotonergic modulators in Alzheimer's disease: a hope in the hopeless condition

Chemistry &Biodiversity, Accepted Article.
Alzheimer disease (AD) is the main cause of dementia worldwide. AD is a progressive brain neurodegenerative disease due to genetic and environmental factors that induce a progressive accumulation of intracellular hyperphosphorylated tau protein and extracellular amyloid protein (Aβ).
Ali I. Al-Gareeb, Morkoss Fakhry, Ali K. Albuhadily, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha   +5 more
wiley   +1 more source

Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. [PDF]

, 1993
Theo Hagg, Silvio Varon
openalex   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine, EarlyView.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
wiley   +1 more source